Dr. Phyllis Tien
Infectious Disease (Infectious Disease Physician)
4150 Clement St, Infectious Diseases Section 111w
San Francisco, CA 94121
At a glance
- In the NPI registry since
- 2006
Licensed in California since 1993, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
CA license G077758 (first issued 1993; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $61.35 in total to this clinician.
| Merck Sharp & Dohme LLC | $33.07 |
|---|---|
| Gilead Sciences, Inc. | $28.28 |
| Food and Beverage | $61.35 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $44,840 in research payments for these studies, mostly to the institutions running them.
- STUDY NAME#Weight gain in persons receiving integrase strand transfer inhibitors INSTIs# Is there an association with plasma drug exposure
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.